

1 SHEPPARD, MULLIN, RICHTER & HAMPTON LLP
2 A Limited Liability Partnership
3 Including Professional Corporations
4 JOHN P. STIGI III, Cal. Bar No. 208342
5 12275 El Camino Real, Suite 100
6 San Diego, California 92130
7 Telephone: 858.720.8900
8 Facsimile: 858.509.3691
9 E mail: jstigi@sheppardmullin.com

10 POLLY TOWILL, Cal. Bar No. 120420
11 MADALYN A. MACARR, Cal. Bar No. 301539
12 TORI KUTZNER, Cal. Bar No. 334057
13 350 South Grand Avenue, 40th Floor
14 Los Angeles, California 90071-3460
15 Telephone: 213.620.1780
16 Facsimile: 213.620.1398
17 E mail: ptowill@sheppardmullin.com
18 mamacarr@sheppardmullin.com
19 tkutzner@sheppardmullin.com

20 Attorneys for Defendants FAT BRANDS, INC.,
21 ANDREW A. WIEDERHORN, KENNETH J.
22 KUICK and ROBERT G. ROSEN

23
24
25
26
27
28

14 UNITED STATES DISTRICT COURT
15 CENTRAL DISTRICT OF CALIFORNIA

16 MITCHELL KATES, Individually
17 and On Behalf of All Others Similarly
18 Situated,

19 Plaintiff,

20 v.

21 FAT BRANDS, INC., ANDREW A.
22 WIEDERHORN, KENNETH J.
23 KUICK, and ROBERT G. ROSEN,

24 Defendants.

25 Case No. 2:24-cv-04775-MWF-MAA

26 The Hon. Michael W. Fitzgerald

27 CLASS ACTION

28 **DEFENDANTS' NOTICE OF
MOTION AND MOTION TO
DISMISS AMENDED COMPLAINT
FOR VIOLATIONS OF THE
FEDERAL SECURITIES LAWS**

*[Request for Judicial Notice and
Declaration of Madalyn Macarr filed
concurrently herewith; [Proposed] Order
submitted concurrently herewith]*

Hearing Date: September 15, 2025

Time: 10:00 a.m.

Department: 5A

Trial Date: None Set

1 **NOTICE OF MOTION AND MOTION**

2 TO LEAD PLAINTIFF AND HIS COUNSEL OF RECORD:

3 PLEASE TAKE NOTICE that on September 15, 2025, at 10:00 a.m. or as soon
4 thereafter as counsel may be heard, in Courtroom 5A of the above-entitled Court,
5 located at 350 West 1st Street, Los Angeles, California, in the courtroom of the
6 Honorable Michael W. Fitzgerald presiding, defendants FAT Brands, Inc., Andrew
7 A. Wiederhorn, Kenneth J. Kuick and Robert G. Rosen will and hereby do move the
8 Court pursuant to Rules 12(b)(6) and 9(b) of the Federal Rules of Civil Procedure and
9 the Private Securities Litigation Reform Act of 1995 (“PSLRA”), 15 U.S.C. §§ 78u-4,
10 *et seq.*, for an order dismissing plaintiff Mitchell Kates’s Amended Class Action
11 Complaint for Violation of the Federal Securities Laws.

12 This motion is brought on the grounds that plaintiff fails to: (1) meet the
13 PSLRA and Rule 9(b) heightened requirements for pleading a claim for violation of
14 Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”),
15 15 U.S.C. § 78j(b), and Securities & Exchange Commission Rule 10b-5, 17 C.F.R.
16 § 240.10b-5, promulgated thereunder, due to plaintiff’s failure to (a) specify action-
17 able misstatements, (b) allege sufficient facts demonstrating the reasons defendants’
18 statements were false or the alleged omissions misleading at the time they were made
19 and (c) allege particularized facts giving rise to a strong inference that defendants
20 made the allegedly false or misleading statements with scienter. Plaintiff’s claim for
21 violation of Section 20(a) of the Exchange Act, 15 U.S.C. § 78t(a), falls with
22 plaintiff’s Section 10(b) claim.

23 This motion is made following the conference of counsel pursuant to Central
24 District of California Local Rule 7-3, which took place on May 22, 2025. (Declaration
25 of Madalyn Macarr ¶2.) Counsel for defendants met and conferred telephonically
26 with plaintiff’s counsel regarding the deficiencies in the Complaint and explained the
27 reasons why the Complaint’s claims are subject to dismissal. (*See id.*) Plaintiff
28 declined to amend or dismiss any portion of his Complaint. (*Id.*)

This motion is based upon this Notice of Motion and Motion, the accompanying Memorandum of Points and Authorities, defendants' Request for Judicial Notice and the Declaration of Madalyn Macarr filed in support thereof, as well as the pleadings and papers on file in this action, any other matters of which this Court may or must take judicial notice and such other oral and/or documentary evidence or argument as may be presented to the Court at or before the time of the hearing.

Dated: June 6, 2025 SHEPPARD, MULLIN, RICHTER & HAMPTON LLP

By: /s/ *John P. Stagi III*

By: _____ /s/ *John P. Stigi III*

JOHN P. STIGI III

POLLY TOWILL

Attorneys for Defendants FAT BRANDS, INC.,
ANDREW A. WIEDERHORN, KENNETH J.
KUICK and ROBERT G. ROSEN

TABLE OF CONTENTS

| | | Page |
|------|--|------|
| I. | INTRODUCTION..... | 1 |
| II. | RELEVANT ALLEGATIONS AND BACKGROUND | 2 |
| | A. FAT Brands, Its Management and Ownership | 2 |
| | B. The <i>Harris</i> Derivative Action..... | 2 |
| | C. The Alleged Wrongdoing at the Core of the Complaint..... | 3 |
| | D. The Allegedly False and/or Misleading Statements and Omissions | 3 |
| | E. The Alleged Corrective Disclosures | 5 |
| III. | LEGAL STANDARDS..... | 6 |
| | A. Motions to Dismiss | 6 |
| | B. Elements of Plaintiff's Claims | 6 |
| | C. Heightened Pleading Standards in Securities Actions | 7 |
| IV. | ARGUMENT | 8 |
| | A. The Complaint's Opinion and Forward-Looking Statement Allegations Are Non-Actionable | 8 |
| | B. The Complaint Fails to Plead Sufficient Facts Showing Why Defendants' Statements Were False or Misleading When Made | 10 |
| | 1. No Undisclosed Intercompany Loan to FCCG Rendered Any Statement False or Misleading..... | 10 |
| | 2. The Company's Risk Disclosures Were Not Misleading..... | 13 |
| | 3. No Facts Show FAT Brands Became a Target of the U.S. Attorney's Investigation Before May 2024..... | 13 |
| | C. The Alleged Item 404 and GAAP Disclosure Violations Do Not State a Section 10(b) Claim | 14 |
| | D. The Alleged Failure to Disclose Contingent Losses Under GAAP Fails | 15 |
| | E. The Complaint Fails to Plead Particularized Facts Giving Rise to a Strong Inference of Scienter..... | 16 |
| | 1. No Alleged Facts Give Rise to a Strong Inference That Kuick Knew About the Unauthorized Intercompany | |

| | | |
|----|--|----|
| 1 | Loans, Much Less That Loan Proceeds Went To Wiederhorn | 16 |
| 2 | 2. No Alleged Facts Give Rise to a Strong Inference That Any Defendant Knew That the Company Was a Target of U.S. Attorney's Investigation | 18 |
| 3 | | |
| 4 | F. The Complaint Fails to State a Controlling Person Liability Claim for Violation of Section 20(a) | 21 |
| 5 | | |
| 6 | V. CONCLUSION | 21 |
| 7 | | |
| 8 | | |
| 9 | | |
| 10 | | |
| 11 | | |
| 12 | | |
| 13 | | |
| 14 | | |
| 15 | | |
| 16 | | |
| 17 | | |
| 18 | | |
| 19 | | |
| 20 | | |
| 21 | | |
| 22 | | |
| 23 | | |
| 24 | | |
| 25 | | |
| 26 | | |
| 27 | | |
| 28 | | |

TABLE OF AUTHORITIES

| | Page(s) |
|---|---------|
| <u>Cases</u> | |
| <i>Abadilla v. Precigen, Inc.</i> 2022 U.S. Dist. LEXIS 96808 (N.D. Cal. May 31, 2022) | 21 |
| <i>In re Apple Sec. Litig.</i> 886 F.2d 1109 (9th Cir. 1989)..... | 10 |
| <i>Ashcroft v. Iqbal</i> 556 U.S. 662 (2009) | 6 |
| <i>In re AXIS Capital Holdings Ltd. Sec. Litig.</i> 456 F. Supp. 2d 576 (S.D.N.Y. 2006)..... | 10 |
| <i>Barron v. Reich</i> 13 F.3d 1370 (9th Cir.1994)..... | 6 |
| <i>Bell Atl. Corp. v. Twombly</i> 550 U.S. 544 (2007) | 6 |
| <i>Branch v. Tunnell</i> 14 F.3d 449 (9th Cir. 1994)..... | 6 |
| <i>Brody v. Transitional Hosps. Corp.</i> 280 F.3d 997 (9th Cir. 2002)..... | 6, 9 |
| <i>Cafasso v. Gen. Dynamics C4 Sys., Inc.</i> 637 F.3d 1047 (9th Cir. 2011)..... | 7 |
| <i>Carr v. Zosano Pharma Corp.</i> 2021 U.S. Dist. LEXIS 166197 (N.D. Cal. Sept. 1, 2021)..... | 12 |
| <i>In re Connetics Corp. Sec. Litig.</i> 542 F. Supp. 2d 996 (N.D. Cal. 2008)..... | 11 |
| <i>Ernst & Ernst v. Hochfelder</i> 425 U.S. 185 (1976) | 7 |
| <i>ESG Capital Partners, LP v. Stratos</i> 2013 WL 12131355 (C.D. Cal. June 26, 2013)..... | 20 |

| | | |
|----|---|---------------|
| 1 | <i>In re Fusion-io, Inc. v. Sec. Litig.</i> 2015 U.S. Dist. LEXIS 18304 (N.D. Cal. Feb. 12, 2015)..... | 15 |
| 2 | | |
| 3 | <i>Gamm v. Sanderson Farms, Inc.</i> 944 F.3d 455 (2d Cir. 2019)..... | 10 |
| 4 | | |
| 5 | <i>Geinko v. Padda</i> 2002 WL 276236 (N.D. Ill. Feb. 27, 2002)..... | 11 |
| 6 | | |
| 7 | <i>Glazer Cap. Mgmt., LP v. Magistri</i> 549 F.3d 736 (9th Cir. 2008)..... | 8, 17 |
| 8 | | |
| 9 | <i>In re Hansen Natural Corp. Sec. Litig.</i> 527 F. Supp. 2d 1142 (C.D. Cal. 2007)..... | 12 |
| 10 | | |
| 11 | <i>Harris v. Junger</i> No. 2021-0511-SG (Del. Ch.) (2022)..... | <i>passim</i> |
| 12 | | |
| 13 | <i>Knox v. Yingli Green Energy Holding Co.</i> 242 F. Supp. 3d 950 (C.D. Cal. 2017)..... | 6 |
| 14 | | |
| 15 | <i>Levi v. Atossa Genetics, Inc.</i> 868 F.3d 784 (9th Cir. 2017)..... | 15 |
| 16 | | |
| 17 | <i>Macquarie Infrastructure Corp. v. Moab Partners, L.P.</i> 601 U.S. 257 (2024) | 14, 15 |
| 18 | | |
| 19 | <i>Mendoza v. HF Foods Grp., Inc.</i> 2021 U.S. Dist. LEXIS 1690982 (C.D. Cal. Aug. 25, 2021)..... | 13 |
| 20 | | |
| 21 | <i>Menkes v. Stolt-Nielsen S.A.</i> 2005 U.S. Dist. LEXIS 28208 (D. Conn. Nov. 10, 2005)..... | 15 |
| 22 | | |
| 23 | <i>Nathanson v. Polycom, Inc.</i> 87 F. Supp. 3d 966 (N.D. Cal. 2015)..... | 17, 18 |
| 24 | | |
| 25 | <i>Nguyen v. Endologix, Inc.</i> 962 F.3d 405 (9th Cir. 2020) | 21 |
| 26 | | |
| 27 | <i>In re NVIDIA Corp. Sec. Litig.</i> 768 F.3d 1046 (9th Cir. 2014) | 7, 21 |
| 28 | | |
| 29 | <i>Omnicare, Inc. v. Laborers Dist. Council Const. Indus. Pension Fund</i> , 135 S. Ct. 1318 (2015) | 9 |

| | | |
|----|---|-------|
| 1 | <i>Oregon Pub. Emps. Ret. Fund v. Apollo Grp. Inc.</i> 774 F.3d 598 (9th Cir. 2014) | 16 |
| 3 | <i>Police Retirement System of St. Louis v. Intuitive Surgical, Inc.</i> 759 F.3d 1051 (9th Cir. 2014) | 8 |
| 5 | <i>Prodanova v. H.C. Wainwright & Co., LLC</i> 993 F.3d 1097 (9th Cir. 2021) | 8, 19 |
| 7 | <i>Purple Mt. Trust v. Wells Fargo & Co.</i> 432 F. Supp. 3d 1095 (N.D. Cal. 2020) | 21 |
| 9 | <i>In re Rigel Pharm., Inc. Sec. Litig.</i> 697 F.3d 869 (9th Cir. 2012) | 7 |
| 10 | <i>In re Sanofi Securities Litigation</i> 155 F. Supp. 3d 386 (S.D.N.Y. 2016) | 11 |
| 12 | <i>South Ferry LP, No. 2 v. Killinger</i> 542 F.3d 776 (9th Cir. 2008) | 20 |
| 14 | <i>Stoneridge Inv. Partners, LLC v. Scientific-Atlanta</i> 552 U.S. 148 (2008) | 6 |
| 16 | <i>In re Sun Microsystems, Inc. Sec. Litig.</i> 1990 U.S. Dist. LEXIS 18740 (N.D. Cal. Aug. 20, 1990) | 10 |
| 18 | <i>Tellabs, Inc. v. Makor Issues & Rights, Ltd.</i> 551 U.S. 308 (2007) | 7, 8 |
| 19 | <i>In re UBS Ag Sec. Litig.</i> 2012 U.S. Dist. LEXIS 141449 (S.D.N.Y. Sept. 28, 2012) | 11 |
| 21 | <i>In re VeriFone Sec. Litig.</i> 11 F.3d 865 (9th Cir. 1993) | 6 |
| 23 | <i>Webb v. SolarCity Corp.</i> 884 F.3d 844 (9th Cir. 2018) | 20 |
| 25 | <i>Zucco Partners, LLC v. Digimarc Corp.</i> 552 F.3d 981 (9th Cir. 2009) | 8, 17 |
| 27 | <u>Statutes</u> | |
| 28 | 15 U.S.C. § 78t(a) | 7, 21 |

| | | |
|----|---|---------------|
| 1 | 15 U.S.C. § 78u-4(b)(1)..... | 7 |
| 2 | 15 U.S.C. § 78u-4(b)(2)..... | 7, 8 |
| 3 | 15 U.S.C. § 78u-4(b)(2)(A) | 7 |
| 4 | 15 U.S.C. § 78u-4, <i>et seq.</i> | 1 |
| 5 | 15 U.S.C. § 78u-5(c)(1)(A)-(B)..... | 9 |
| 6 | PSLRA | <i>passim</i> |
| 7 | Securities Exchange Act of 1934 § 10(b)..... | <i>passim</i> |
| 8 | Securities Exchange Act of 1934 § 20(a) | 1, 7, 21 |
| 9 | | |
| 10 | <u>Other Authorities</u> | |
| 11 | 17 C.F.R. § 229.404..... | 5, 14, 15 |
| 12 | Fed. R. Civ. P. 9(b)..... | 1, 7, 10, 12 |
| 13 | | |
| 14 | Fed. R. Civ. P. 12(b)(6) | 1 |
| 15 | Rule 10b-5..... | <i>passim</i> |
| 16 | | |
| 17 | | |
| 18 | | |
| 19 | | |
| 20 | | |
| 21 | | |
| 22 | | |
| 23 | | |
| 24 | | |
| 25 | | |
| 26 | | |
| 27 | | |
| 28 | | |

1 Defendants FAT Brands, Inc. (“FAT Brands” or the “Company”), Andrew
2 Wiederhorn (“Wiederhorn”), Kenneth Kuick (“Kuick”) and Robert Rosen (“Rosen”)
3 respectfully submit this memorandum in support of their motion to dismiss lead plain-
4 tiff’s Amended Class Action Complaint (the “Complaint”) for failure to state a claim
5 for relief under Federal Rules of Civil Procedure 12(b)(6) and 9(b) and the Private
6 Securities Litigation Reform Act of 1995 (“PSLRA”), 15 U.S.C. § 78u-4, *et seq.*

7 **I. INTRODUCTION**

8 Plaintiff brings this putative securities class action on behalf of a class of pur-
9 chasers of FAT Brands securities between March 23, 2022 and May 10, 2024, alleging
10 violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The
11 gravamen of the Complaint is that defendants failed to disclose certain purportedly
12 unauthorized intercompany loans between FAT Brands and its former parent entity
13 allegedly orchestrated by FAT Brands’ former CEO, Wiederhorn, to serve his own
14 financial interests. According to the Complaint, these transactions—and the Com-
15 pany’s lack of disclosures concerning them—misled investors and artificially inflated
16 FAT Brands’ stock price.

17 Plaintiff’s complaint relies principally upon allegations and theories advanced
18 years ago in a separate shareholder derivative action, as well as in the subsequent
19 indictment of FAT Brands and Wiederhorn by the U.S. Attorney’s Office and
20 parallel civil enforcement action by the Securities and Exchange Commission
21 (“SEC”) in May 2024. Based solely upon those sources, plaintiff asserts that defen-
22 dants made materially false or misleading statements regarding the existence and
23 approval of intercompany loans, the status of ongoing governmental investigations
24 and the Company’s cooperation with regulatory authorities.

25 Plaintiffs’ claims are deficient for multiple reasons. The Complaint fails to
26 plead falsity or scienter with the particularity required by the PSLRA and Rule 9(b),
27 relies almost exclusively upon conclusory and hearsay allegations that merely echo
28 other proceedings and fails to identify an actionable misrepresentation or omission.

1 For these reasons, as well as the additional reasons detailed herein, the Complaint
2 fails to state a claim upon which relief can be granted, and should be dismissed in
3 its entirety.

4 **II. RELEVANT ALLEGATIONS AND BACKGROUND**

5 **A. FAT Brands, Its Management and Ownership**

6 FAT Brands is a restaurant franchisor that generates revenues by charging its
7 franchisees an initial franchise fee and ongoing royalty fees. (Complaint ¶¶2, 25.)
8 Wiederhorn served as FAT Brands' CEO beginning in 2006. (*Id.* ¶36.)

9 Before FAT Brands' 2017 initial public offering ("IPO"), Fog Cutter Capital
10 Group Inc. ("FCCG"), a privately held company controlled by Wiederhorn, owned
11 100 percent of FAT Brands' common stock and voting power. (*Id.* ¶¶29, 36, 42.)
12 Following the IPO, FCCG retained 80 percent of FAT Brands' common stock and
13 voting power. (*Id.* ¶¶43, 77.) FCCG merged with FAT Brands in December 2020
14 (the "Merger"). (*Id.* ¶¶36, 42, 63.)

15 **B. The *Harris* Derivative Action**

16 On June 15, 2021, two FAT Brands shareholders filed a shareholder derivative
17 action against Wiederhorn and other FAT Brands directors in the Delaware Court of
18 Chancery, entitled *Harris v. Junger*, No. 2021-0511-SG (Del. Ch.) ("Harris"). (Com-
19 plaint ¶52.) In *Harris*, plaintiffs alleged that Wiederhorn caused FCCG to issue to
20 himself personal loans "over the course of the past several years" (the "Shareholder
21 Loans"), then caused FAT Brands to issue FCCG intercompany loans to cover the
22 Shareholder Loans (the "Intercompany Loans"). (RJN, Ex. A (*Harris* Complaint),
23 ¶5). Wiederhorn then allegedly caused FCCG to forgive his Shareholder Loans with-
24 out any repayment, and then caused the merger of FAT Brands and FCCG to eliminate
25 the Intercompany Loans. (Complaint ¶¶56, 57 (citing RJN, Ex. A, ¶15).) Plaintiffs
26 in *Harris* allege that in early 2020, the companies entered into an Intercompany
27 Revolving Credit Agreement ("IRCA") which, to reflect the already then outstanding
28 indebtedness, carried an initial balance of \$21,067,000 (measured as of December 29,

1 2019). This balance receivable from FCCG had, by March 29, 2020, increased to
2 \$26,854,000 and, by September 27, 2020, to more than \$38 million. (RJN, Ex. A,
3 ¶¶7, 50.) According to plaintiffs in *Harris*, and as parroted by plaintiff here, “[t]here
4 **never** was a business justification for these loans.” (Complaint ¶59; RJN, Ex. A, ¶8
5 (emphasis in original).)

6 **C. The Alleged Wrongdoing at the Core of the Complaint**

7 The Complaint here—like the *Harris* Complaint upon which it draws—alleges
8 that Wiederhorn “looted” FAT Brands by causing “FCCG to loan him tens of millions
9 of dollars, and then caus[ing] FAT Brands to loan the money to FCCG to cover those
10 debts,” and “then caus[ing] the merger of FAT Brands and FCCG to dissolve the
11 intercompany loans” without repayment from FCCG. (Complaint ¶¶54, 61, 67; *see also id.* ¶72 (“Effective with the Merger with FCCG, the Intercompany Agreement
13 was terminated and intercompany balances were eliminated in consolidation”)).

14 Plaintiff nonetheless focuses the Complaint on a small subset of the overall
15 alleged “looting” allegations, namely approximately \$9.6 million in alleged Inter-
16 company Loans made in 2020 which, contrary to certain terms in the IRCA, allegedly
17 were not approved by FAT Brands’ Board of Directors in advance. (*Id.* ¶99.) From
18 there, the Complaint alleges that “Wiederhorn’s misuse of corporate funds, securities
19 fraud, and tax evasion” resulted in investigations by the Department of Justice
20 (“DOJ”) and the SEC (*id.* ¶4), which investigations ultimately resulted in the U.S.
21 Attorney’s Office indicting FAT Brands and Wiederhorn, and the SEC filing a com-
22 plaint against FAT Brands and Wiederhorn in May 2024 (the “Indictment” and the
23 “SEC Complaint,” respectively). (Complaint ¶¶8, 100, 104.)

24 **D. The Allegedly False and/or Misleading Statements and Omissions**

25 Plaintiff first challenges the Company’s statement that, other than the trans-
26 actions disclosed in specific notes to the Company’s audited consolidated financial
27 statements in its annual report for the fiscal year ended December 26, 2021 filed on
28 March 23, 2022 (the “2021 Annual Report”):

1 [S]ince December 29, 2019, there has not been, nor is there currently
2 proposed, any transaction or series of similar transactions to which we
3 were or will be a party: in which the amount involved exceeds \$120,000;
4 and in which any director, executive officer, shareholder who beneficially
owns 5% or more of our common stock or any member of their
immediate family had or will have a direct or indirect material interest.

5 (Complaint ¶72.) Plaintiff contends this statement was false or misleading because
6 FAT Brands did not disclose the approximately \$9.6 million in alleged
7 Intercompany Loans FAT Brands made to FCCG in 2020 that supposedly lacked
8 prior Board approval. (*Id.* ¶73.)

9 Plaintiff next contends that a disclosed “Risk Factor” in the Company’s Form
10 424B5 Prospectus Supplement filed on November 14, 2022, was misleading for the
11 same reason. Specifically, the Company disclosed that FAT Brands was “controlled
12 by [FCCG]” and warned that FCCG’s interests “may differ from those of our public
13 stockholders.” (Complaint ¶77.) Plaintiff nevertheless attacks this “Risk Factor” as
14 misleading because it did not tell investors that Wiederhorn had already been using
15 FCCG to “loot[] the Company.” (*Id.* ¶78.)

16 With respect to governmental investigations, the Company allegedly disclosed,
17 in various periodic reports, that the U.S. Attorney’s Office and the SEC informed it
18 in December 2021 that they had opened investigations relating to the Company and
19 Wiederhorn concerning, among other things, the companies’ Merger and transactions
20 between these entities and Wiederhorn. (*Id.* ¶¶74, 80, 87, 90, 93, 96.) The Company
21 further disclosed that it “intends to cooperate with the U.S. Attorney and the SEC
22 regarding these matters and is continuing to actively respond to inquiries and requests
23 from [them].” (*Id.*)¹ Finally, the Company advised investors that “[w]e believe that
24 the Company is not currently a target of the U.S. Attorney’s investigation.” (*Id.*)²

25
26 ¹ The iteration of this statement in the 2021 Annual Report stated that “[t]he Company
is cooperating with the government regarding these matters.” (Complaint ¶74.)

27 ² This statement was repeated in the Company’s 2021 Annual Report, annual report
28 for the fiscal year ended December 25, 2022 filed on February 24, 2023, and quarterly reports for the fiscal quarters ended March 6, 2023, June 25, 2023 and Septem-

1 Plaintiff contends these disclosures were false or misleading because, assuming
2 defendants were indeed cooperating with the government's requests, they "should
3 have known, or were reckless in not knowing, that FAT Brands was a target of the
4 investigation for its role in funneling money from investors to [Wiederhorn]." (*Id.*
5 ¶¶75, 81, 88, 91, 94.) Plaintiff contends that the Company misled investors by
6 "assur[ing] investors that the Company was not the target of the investigation" and by
7 "stating that the Company was not a target of the investigation," when in fact it was.
8 (*Id.*) In the alternative, plaintiff alleges that defendants misled investors by stating
9 that the Company was cooperating with the governmental investigation, when "in
10 truth they were not cooperating." (*Id.*)

11 As a separate theory of omissions-based liability, plaintiff alleges that, by fail-
12 ing to disclose the Intercompany Loans as "material related party transactions," defen-
13 dants violated their duty to disclose under Item 404(a) of Regulation S-K, 17 C.F.R.
14 § 229.404 ("Item 404"), and U.S. Generally Accepted Accounting Principles
15 ("GAAP"). (Complaint ¶108.)

16 Lastly, plaintiff alleges that defendants also violated GAAP by failing to dis-
17 close "contingent losses" relating to and arising out of the U.S. Attorney's and SEC's
18 investigations. (*Id.* ¶127.)

19 **E. The Alleged Corrective Disclosures**

20 Plaintiff alleges that defendants partially "revealed the truth" starting on March
21 12, 2024, when the Company filed its annual report for the fiscal year ended
22 December 31, 2023 and excluded the language included in its prior SEC filings that
23 "[w]e believe that the Company is not currently a target of the U.S. Attorney's
24 investigation." (*Id.* ¶¶96, 97.) Plaintiff construes this as an admission that the Com-
25 pany had previously been a target of that investigation. (*Id.* ¶97.) According to plain-
26

27 ber 24, 2023 filed on May 9, 2023, August 4, 2023, and October 31, 2023, respec-
28 tively. (Complaint ¶¶80, 87, 90, 93, 96.)

1 tiff, the truth became “fully exposed” on May 10, 2024, when the U.S. Attorney’s
2 Office announced the indictment of FAT Brands and Wiederhorn (*id.* ¶100) and the
3 SEC announced that it had filed the SEC Complaint against FAT Brands and
4 Wiederhorn. (*Id.* ¶104.)

5 III. LEGAL STANDARDS

6 A. Motions to Dismiss

7 “To survive a motion to dismiss, a complaint must contain sufficient factual
8 matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’”
9 *Ashcroft v. Iqbal*, 556 U.S. 662, 678 (2009) (quoting *Bell Atl. Corp. v. Twombly*, 550
10 U.S. 544, 570 (2007)). Although a court must accept the factual allegations in the
11 pleadings as true, the court need not accept as true conclusory allegations of law and
12 unwarranted inferences. *In re VeriFone Sec. Litig.*, 11 F.3d 865, 868 (9th Cir. 1993).
13 The court also may consider additional facts in materials of which it may take judicial
14 notice (*Barron v. Reich*, 13 F.3d 1370, 1377 (9th Cir.1994)), as well as “documents
15 whose contents are alleged in a complaint and whose authenticity no party questions,
16 but which are not physically attached to the pleading.” *Branch v. Tunnell*, 14 F.3d
17 449, 454 (9th Cir. 1994).

18 B. Elements of Plaintiff’s Claims

19 To state a Section 10(b) claim, a plaintiff must allege (1) a material misrepre-
20 sentation or omission by the defendant (*i.e.*, falsity); (2) scienter; (3) a connection
21 between the misrepresentation or omission and the purchase or sale of a security; (4)
22 reliance upon the misrepresentation or omission; (5) economic loss; and (6) loss caus-
23 ation. *Stoneridge Inv. Partners, LLC v. Scientific-Atlanta*, 552 U.S. 148, 157 (2008).
24 A statement or omission is actionable only if it “affirmatively create[s] an impression
25 of a state of affairs that differs in a material way from the one that actually exists.”
26 *Brody v. Transitional Hosps. Corp.*, 280 F.3d 997, 1006 (9th Cir. 2002); *see also Knox*
27 *v. Yingli Green Energy Holding Co.*, 242 F. Supp. 3d 950, 963 (C.D. Cal. 2017) (state-
28 ments amounting to “fraud by hindsight” are not actionable).

1 Section 20(a) creates liability for “controlling persons.” 15 U.S.C. § 78t(a).
2 “To establish a cause of action under this provision, a plaintiff must first prove a
3 primary violation of underlying federal securities laws, such as Section 10(b) or Rule
4 10b-5, and then show that the defendant exercised actual power over the primary
5 violator.” *In re NVIDIA Corp. Sec. Litig.*, 768 F.3d 1046, 1052 (9th Cir. 2014) (cita-
6 tion omitted).

7 **C. Heightened Pleading Standards in Securities Actions**

8 Section 10(b) claims must meet the heightened pleading requirements set forth
9 in Federal Rule of Civil Procedure 9(b) and the PSLRA. *See In re Rigel Pharm., Inc.*
10 *Sec. Litig.*, 697 F.3d 869, 876 (9th Cir. 2012); 15 U.S.C. § 78u-4(b)(2)(A). Under
11 Rule 9(b), plaintiffs must “state with particularity the circumstances constituting fraud
12 or mistake.” Fed. R. Civ. P. 9(b). The complaint must identify the “who, what, when,
13 where, and how” of the fraudulent misconduct, “as well as what is false or misleading
14 about” the fraud, and “why it is false.” *Cafasso v. Gen. Dynamics C4 Sys., Inc.*, 637
15 F.3d 1047, 1055 (9th Cir. 2011) (citation omitted).

16 The PSLRA requires plaintiffs to state with particularity both the facts
17 constituting the alleged violation and the facts evidencing scienter. *See Tellabs, Inc.*
18 *v. Makor Issues & Rights, Ltd.*, 551 U.S. 308, 313 (2007). It enhances Rule 9(b)’s
19 particularity requirement by “providing that a securities fraud complaint identify: (1)
20 each statement alleged to have been misleading; (2) the reason or reasons why the
21 statement is misleading; and (3) all facts on which that belief is formed.” 15 U.S.C.
22 § 78u-4(b)(1). The statute also requires, as to each allegedly misleading statement or
23 omission, that plaintiff “state with particularity” as to each defendant “facts giving
24 rise to a strong inference that the defendant acted with the required state of mind,”
25 *i.e.*, scienter. 15 U.S.C. § 78u-4(b)(2).

26 “Scienter” refers to a “mental state embracing intent to deceive, manipulate, or
27 defraud.” *Ernst & Ernst v. Hochfelder*, 425 U.S. 185, 193 n.12 (1976). A defendant
28 acts with scienter only if he makes false or misleading statements either intentionally

1 or with deliberate recklessness. *See Zucco Partners, LLC v. Digimarc Corp.*, 552
2 F.3d 981, 991 (9th Cir. 2009).

3 A plaintiff must “state with particularity facts giving rise to a *strong* inference
4 that the defendant acted with the required state of mind.” 15 U.S.C. § 78u-4(b)(2)
5 (emphasis added). “To qualify as ‘strong’ within the intendment of . . . the PSLRA
6 . . . an inference of scienter must be more than merely plausible or reasonable—it
7 must be cogent and at least as compelling as any opposing inference of nonfraudulent
8 intent.” *Tellabs*, 551 U.S. at 314. Thus, to meet the PSLRA’s high burden for pleading
9 scienter, a complaint cannot rely on “mere motive and opportunity or recklessness,
10 but rather, must state specific facts indicating no less than a degree of recklessness
11 that strongly suggests actual intent.” *Prodanova v. H.C. Wainwright & Co., LLC*, 993
12 F.3d 1097, 1108 (9th Cir. 2021). Allegations the defendants “should have known” of
13 the violations are insufficient. *See Glazer Cap. Mgmt., LP v. Magistri*, 549 F.3d 736,
14 748 (9th Cir. 2008). Instead, plaintiffs must allege facts “linking specific reports and
15 their contents to the executives.” *See Police Retirement System of St. Louis v. Intuitive
16 Surgical, Inc.*, 759 F.3d 1051, 1063 (9th Cir. 2014).

17 IV. ARGUMENT

18 A. The Complaint’s Opinion and Forward-Looking Statement Allegations 19 Are Non-Actionable

20 Plaintiff challenges as false or misleading the Company’s statement that “*we*
21 *believe* that the Company is not *currently* a target of the U.S. Attorney’s investiga-
22 tion.” (Complaint ¶¶74, 80, 87, 90, 93) (emphasis added).) Contrary to plaintiff’s re-
23 characterization of this statement, it did not “assure[] investors that the Company was
24 not the target of the investigation,” nor did it “stat[e] that the Company was not a
25 target of the investigation.” (*Id.* ¶¶85, 81, 88, 91, 94, 99.) It also did not suggest,
26 much less assure, that the Company would never become a target of the U.S. At-
27 torney’s investigation.

28

1 “We believe” is a classic and unmistakable opinion statement. *See Omnicare,*
2 *Inc. v. Laborers Dist. Council Const. Indus. Pension Fund*, 135 S. Ct. 1318, 1326
3 (2015). Such statement is actionable only if the speaker did not truly hold the opinion
4 or when it misleadingly convey facts regarding how the speaker formed the opinion
5 or the basis for the opinion. *Id.* at 1322 (explaining that an opinion statement cannot
6 be misleading absent identification of “particular (and material facts) going to the
7 basis for the issuer’s opinion . . . whose omission made the opinion statement at issue
8 misleading.”) Plaintiff does not allege any facts—let alone particularized facts—sug-
9 gesting the absence of a factual basis for the opinion statement. Accordingly, plaintiff
10 fails to plead the falsity of the “we believe” statement sufficient to meet the pleading
11 standard of the PSLRA.

12 The “we believe” statement also did not suggest a state of affairs inconsistent
13 with the one that actually existed. *Brody*, 280 F.3d at 1006. Plaintiff alleges no facts
14 showing that, at any time this statement was made, FAT Brands actually was a target
15 of the U.S. Attorney’s investigation. In fact, no alleged facts reveal the point at which
16 FAT Brands became a target. (*See* RJD Ex. B (Indictment), ¶6 (alleging that in
17 December 2021, Wiederhorn and FAT Brands “learned that defendant WIEDER-
18 HORN was *the* target of a federal criminal investigation”) (emphasis added).)³

19 Plaintiff also challenges as false and misleading the statement that the
20 “Company intends to cooperate with the U.S. Attorney and the SEC regarding these
21 matters.” (Complaint ¶¶80, 87, 90, 93.) That statement of future intent is a clearly
22 designated forward-looking statement. Plaintiff alleges no facts showing that, when
23 the Company made the statement, it did not genuinely intend to cooperate. Hence,
24 the Complaint fails to plead the requisite “actual knowledge of the statement’s
25 falsity.” 15 U.S.C. § 78u-5(c)(1)(A)-(B). Although plaintiff states in conclusory
26

27 ³ The Complaint also alleges no subsequent corrective disclosure relating to this alleg-
28 edly misleading opinion statement. (*See* Complaint ¶97 (attempting to suggest that
the non-inclusion of the challenged opinion statement in a later periodic report con-
stituted an “admission” and corrective disclosure).)

1 terms—as an alternative factual theory—that the Company was not in fact cooperat-
2 ing, no particularized allegations show a lack of cooperation or an intent to cooperate
3 in the future. In fact, plaintiff’s “should have known”-it-was-a-target scienter theory
4 hinges upon defendants’ having learned the information through the Company’s
5 cooperation with the U.S. Attorney’s Office in responding to document requests.
6 (Complaint, ¶¶81, 88, 91, 94.)⁴

7 **B. The Complaint Fails to Plead Sufficient Facts Showing Why Defendants’
8 Statements Were False or Misleading When Made**

9 **1. No Undisclosed Intercompany Loan to FCCG Rendered Any
10 Statement False or Misleading**

11 The thrust of plaintiff’s allegations is that the Company failed to disclose
12 approximately \$9.6 million in purportedly unapproved Intercompany Loans in 2020.
13 (Complaint ¶73), and that this failure rendered the Company’s statements about its
14 related party transactions false and misleading.⁵

15 First, the Complaint fails to allege with the requisite particularity that the alleg-
16 edly omitted “looting” or other illegal conduct actually occurred. This itself is fatal
17 to plaintiff’s claims. “[W]hen a complaint claims that statements were rendered false
18 or misleading through the non-disclosure of illegal activity, the facts of the underlying
19 illegal acts must also be pleaded with particularity, in accordance with the heightened
20 pleading requirement of Rule 9(b) and the PSLRA.” *Gamm v. Sanderson Farms, Inc.*,
21 944 F.3d 455, 465 (2d Cir. 2019); *see also In re AXIS Capital Holdings Ltd. Sec.*
22

23 ⁴ Plaintiff’s allegation that defendants did not actually cooperate or intend to
24 cooperate with the government is contradicted by his own admission that the
25 Company formed and maintained a Special Review Committee, comprised of
directors other than Wiederhorn, to oversee a review of the issues raised by the U.S.
Attorney and SEC investigations. (Complaint, ¶¶80, 87.)

26 ⁵ When a single claim is based upon multiple alleged disclosure violations, a state-
27 ment-by-statement analysis is appropriate, as it promotes efficiency by narrowing
the scope of discovery and isolating issues that are susceptible to resolution by later
28 motion practice. *See, e.g., In re Apple Sec. Litig.*, 886 F.2d 1109, 1116 (9th Cir.
1989); *In re Sun Microsystems, Inc. Sec. Litig.*, 1990 U.S. Dist. LEXIS 18740 (N.D.
Cal. Aug. 20, 1990).

1 *Litig.*, 456 F. Supp. 2d 576 (S.D.N.Y. 2006) (dismissing Section 10(b) claims depen-
2 dent upon predicate allegation that company participated in anticompetitive scheme
3 where complaint did not allege sufficient facts to show company actually engaged in
4 the alleged scheme). Here, however, to allege falsity, the Complaint relies *exclusively*
5 upon unproven allegations lifted nearly *verbatim* from the *Harris* Complaint, the
6 Indictment and the SEC Complaint. Significantly, plaintiff does not allege he has any
7 independent information to support his allegations apart from the recycled allegations
8 from other complaints. (Complaint at 2.)

9 This falls far short of meeting the PSLRA's standards. *See In re Sanofi Securi-*
10 *ties Litigation*, 155 F. Supp. 3d 386, 398-400 (S.D.N.Y. 2016) (plaintiffs failed to
11 plausibly allege illegal conduct underlying section 10(b) claim because ““upon infor-
12 mation and . . . belief” allegation from a different lawsuit incorporated into the CAC
13 does not suffice under the PSLRA.”) Courts need not consider uncorroborated alle-
14 gations parroted from a complaint in another action for which plaintiffs’ counsel has
15 not conducted an independent investigation. *In re UBS Ag Sec. Litig.*, 2012 U.S. Dist.
16 LEXIS 141449, at *53 n.17 (S.D.N.Y. Sept. 28, 2012); *see also In re Connetics Corp.*
17 *Sec. Litig.*, 542 F. Supp. 2d 996, 1005 (N.D. Cal. 2008) (“plaintiffs cite no authority
18 that . . . an attorney may rely *entirely* on another complaint as the *sole* basis for his or
19 her allegations” and striking allegations parroted from SEC complaint where plaintiff
20 did “not contend that they conducted independent investigation into the facts alleged
21 in the SEC complaint or had any additional bases for the specific allegations”)
22 (emphasis in original); *Geinko v. Padda*, 2002 WL 276236, at *6 (N.D. Ill. Feb. 27,
23 2002) (“hearsay allegations that Plaintiffs offer in their Amended Complaint are
24 improper, and therefore superfluous, and they will not be considered”). Because the
25 Complaint relies exclusively upon these second-hand allegations to plead the alleg-
26 edly omitted facts, plaintiff’s claims, to the extent based on these allegedly omitted
27 facts, necessarily fail.

28

1 Notably, the Complaint lacks *any* allegations attributable to confidential wit-
2 nesses (CWs) or former employees (FEs) of FAT Brands. This is a “red-flag” that
3 undermines the sufficiency of the Complaint under the PSLRA. *See Carr v. Zosano*
4 *Pharma Corp.*, 2021 U.S. Dist. LEXIS 166197, at *31-32 (N.D. Cal. Sept. 1, 2021)
5 (dismissing Rule 10b-5 claim for failing to plead scienter where plaintiffs “fail to
6 include any allegations against Defendants from confidential witnesses or former
7 Zosano employees,” and “[a]s a result, their complaint lacks notable features that tend
8 to be ‘hallmarks of a potentially viable securities claim’”); *In re Hansen Natural*
9 *Corp. Sec. Litig.*, 527 F. Supp. 2d 1142, 1163 (C.D. Cal. 2007) (dismissing Rule 10b-
10 5 claim where the plaintiff’s allegations were “all based on publicly-filed documents
11 —and not, as is the case in many securities fraud cases, on the statements of confi-
12 dential witnesses and/or employees and former employees”).

13 Even if considered, none of the *Harris* Action, Indictment and SEC Complaint-
14 sourced allegations sufficiently demonstrate the falsity of the Company’s related party
15 transaction statements. This is because the Complaint fails to identify with the parti-
16 cularity required under the PSLRA and Rule 9(b) that any related party transaction
17 actually took place that should have been but was not disclosed. Indeed, the Com-
18 pany’s long history of related-party transactions with FCCG was thoroughly disclosed
19 to the investing public. For example, Note 3 (expressly incorporated by referenced
20 into the 2021 Annual Report) disclosed that:

21 FCCG historically made loan advances to Andrew A. Wiederhorn, its
22 CEO and significant stockholder (the “Stockholder Loan”). Prior to the
23 Merger, the Stockholder Loan was cancelled, and the balance recorded
24 as a loss by FCCG on forgiveness of loan to stockholder.

25 (RJN, Ex. D, Note 3.) Note 12 (also incorporated by reference) disclosed that, in
26 connection with the Merger, certain debts of FCCG totaling \$12.5 million were
27 assumed by Fog Cutter Acquisition LLC, a wholly-owned subsidiary of the Company.
(*Id.*, Note 12.)

1 Plaintiff complains that the Company violated the IRCA by failing to obtain
2 prior board approval for all of the Intercompany Loans made in 2020, and failed to
3 disclose its non-compliance with the IRCA’s board-approval provisions. (Complaint
4 ¶99.) But these corporate governance provisions plainly constituted and operated as
5 an internal FAT Brands corporate governance policy only. (*See id.* ¶72.) “[W]hether
6 a company violated its own internal policy is a matter of internal management and
7 ‘Congress by § 10(b) did not seek to regulate transactions which constitute no more
8 than internal corporate mismanagement.’” *Mendoza v. HF Foods Grp., Inc.*, 2021
9 U.S. Dist. LEXIS 1690982, at *20-22 (C.D. Cal. Aug. 25, 2021) (citation omitted).

10 **2. The Company’s Risk Disclosures Were Not Misleading**

11 Plaintiff contends the Company’s disclosure of the risk that FCCG’s interests
12 “may differ from those of our public stockholders” given that FAT Brands was “con-
13 trolled by [FCCG]” was misleading because it did not warn investors that Wiederhorn
14 had already been “looting the Company” through the Intercompany Loans. (Com-
15 plaint ¶78.) For the same reasons discussed above (Section IV.C.1), the Section 10(b)
16 claim fails to the extent premised upon this omissions-based statement.

17 **3. No Facts Show FAT Brands Became a Target of the U.S.
18 Attorney’s Investigation Before May 2024**

19 Even assuming that the Company’s statements that it “believed” it was not
20 “currently” a target of the U.S. Attorney’s investigation is actionable, the allegation
21 still fails to state a claim because the Complaint contains no facts showing when FAT
22 Brands actually became a target of that investigation. In other words, no alleged
23 facts show that the Company’s stated belief was actually false at the time the state-
24 ments were made, or that defendants knew at any time during the Class Period of any
25 existing facts that should have been disclosed to make the statements not misleading.

26 Moreover, the Complaint’s theory with respect to these statements is *not* that
27 any defendant actually knew, but that they should have known or were reckless in not
28 knowing, that the Company was a target of the government’s investigations. (Com-

1 plaintiff ¶¶75, 81, 88, 91.) But neither the Complaint, the *Harris* Complaint, the Indict-
2 ment nor the SEC Complaint shed *any* light on when the Company, as distinct from
3 Wiederhorn, became an investigation target. Thus, the Company’s stated belief that
4 it was not “currently” a target of the investigation was neither false nor misleading.

5 **C. The Alleged Item 404 and GAAP Disclosure Violations Do Not State a
6 Section 10(b) Claim**

7 Recognizing that his omission theory does not show a disclosure that was
8 necessary to make any of their challenged statements not misleading, plaintiff turns
9 to Item 404 and GAAP as the sources of independent duties to disclose approximately
10 \$9.6 million in Intercompany Loans made in 2020 as well as alleged “round-tripping”
11 of Company funds as “related party transactions” in the Company’s SEC filings dur-
12 ing the Class Period. (*Id.* ¶107.) The Complaint asserts that the Company’s 2021
13 Annual Report was misleading simply because the Company “did not[] disclose”
14 these transactions. (*Id.* ¶¶113, 126.) Plaintiff’s “pure omissions” theory fails under
15 recent Supreme Court precedent.

16 In *Macquarie Infrastructure Corp. v. Moab Partners, L.P.*, 601 U.S. 257, 265
17 (2024), the Supreme Court resolved a circuit split and confirmed that a duty to dis-
18 close arising independent of Rule 10b-5 is insufficient by itself to render silence mis-
19 leading under Rule 10b-5. Instead, to state a claim, “the Rule requires identifying
20 affirmative assertions (*i.e.*, ‘statements made’) before determining if other facts are
21 needed to make those statements ‘not misleading.’” *Id.* at 264. Thus, in *Macquarie*,
22 “the failure to disclose information required by Item 303 [of Regulation S-K] can
23 support a Rule 10b-5(b) claim only if the omission renders affirmative statements
24 made misleading.” *Id.* at 265. “Pure omissions,” however, “are not actionable under
25 Rule 10b-5(b).” *Id.* at 260. *Macquarie*’s holding is based on Rule 10b-5’s “[l]ogic[]
26 and plain text” and so applies whether the alleged source of the disclosure duty is Item
27 303 or, as is the case here, Item 404 or SEC regulations imposing GAAP-related dis-
28 closure obligations. *Id.* at 264.

1 Plaintiff fails to point to any “affirmative statements made misleading” by the
2 Company’s alleged failure to disclose “related party transactions” under Item 404 and
3 GAAP. *See id.* at 265; *see also Levi v. Atossa Genetics, Inc.*, 868 F.3d 784, 800 (9th
4 Cir. 2017). This “pure omissions” theory cannot form the basis of a Rule 10b-5 claim.
5 *See Macquarie*, 601 U.S. at 264; *see also In re Fusion-io, Inc. v. Sec. Litig.*, 2015 U.S.
6 Dist. LEXIS 18304, at *54-55 (N.D. Cal. Feb. 12, 2015) (“[E]ven if Defendants had
7 a duty [to disclose] under [Regulation S-K] . . . , their failure to do so cannot form a
8 basis for Plaintiffs’ § 10(b) claim.”).⁶ Plaintiff thus fails to state a Section 10(b) claim
9 to the extent he relies on a “duty to disclose” arising out of Item 404 or GAAP.

10 **D. The Alleged Failure to Disclose Contingent Losses Under GAAP Fails**

11 Lastly, plaintiff alleges that defendants violated a duty to disclose “contingent
12 losses” relating to and arising out of the U.S. Attorney’s and SEC’s investigations, as
13 allegedly required by GAAP. (Complaint ¶127.) However, plaintiff’s theory runs
14 into the same issue as its other GAAP-based theory, which is that he fails to
15 specifically identify any “affirmative statements made misleading” by the Company’s
16 alleged non-disclosure of contingent losses, instead relying on a “pure omissions”
17 theory that cannot support a Rule 10b-5 claim. (*See Section IV.D, supra.*) And even
18 if plaintiff had pointed to an affirmative statement, he again fails to allege sufficient
19 facts to show that “FAT Brands was required to disclose a loss contingency associated
20 with the SEC and DOJ investigations at the beginning of the Class Period” under
21 GAAP. (Complaint ¶127.) His assertion that defendants could “reasonably estimate”
22 the amount of any loss resulting from the Intercompany Loans “as soon as the DOJ
23

24 ⁶ Plaintiff further fails to explain how either Item 404 or GAAP could possibly extend
25 to this sort of unilateral and “illicit” looting behavior. (*See Complaint ¶4* (alleging
26 Wiederhorn “misused” corporate funds); *id.* ¶¶78, 141-42 (alleging transfers were
27 “unauthorized” by the Company)); *see also Menkes v. Stolt-Nielsen S.A.*, 2005 U.S.
28 Dist. LEXIS 28208, at *28-29 (D. Conn. Nov. 10, 2005) (“To construe the disclosure
requirements [in Regulation S-K] to compel disclosure of Stoelt’s alleged criminal
actions in this case would eviscerate the well-established principle that Rule
10b-5 generally does not ‘require management to accuse itself of antisocial or illegal
policies.’”) (citation omitted).

1 and SEC had manifested an awareness of a possible claim against FAT Brands as part
2 of its investigation” is not supported by any facts in the Complaint. (*Id.* ¶145.) In
3 fact, nowhere does the Complaint provide any indication as to when the Company, as
4 opposed to Wiederhorn, became an investigation target, let alone when any defendant
5 became aware of that development. Plaintiff thus fails to allege that a loss arising
6 from the investigations and the Intercompany Loans was “reasonably possible.” *See*
7 ASC 450-20-55-13 (“The filing of a suit . . . does not automatically indicate that
8 accrual of a loss may be appropriate. The degree of probability of an unfavorable
9 outcome must be assessed.”). Absent such facts, and paired with clear disclosures
10 about the investigations related to Wiederhorn, plaintiff has failed to show that
11 defendants were required to disclose a loss contingency under GAAP.

12 **E. The Complaint Fails to Plead Particularized Facts Giving Rise to a
13 Strong Inference of Scienter**

14 In order to meet the PSLRA’s exacting standards, a plaintiff must “allege scienter
15 with respect to *each* of the individual defendants.” *See Oregon Pub. Emps. Ret.*
16 *Fund v. Apollo Grp. Inc.*, 774 F.3d 598, 607 (9th Cir. 2014) (emphasis added).

17 **1. No Alleged Facts Give Rise to a Strong Inference That Kuick
18 Knew About the Unauthorized Intercompany Loans, Much Less
19 That Loan Proceeds Went To Wiederhorn**

20 With respect to the Company’s alleged failure to disclose the unauthorized
21 Intercompany Loans, plaintiff fails to plead *any* facts—much less particularized facts
22—giving rise to a strong inference that Kuick or Rosen acted with scienter. With
23 respect to the alleged falsity of the challenged related-party-transaction statement, the
24 Complaint alleges only that, “as the mastermind orchestrating the illicit self-dealing
25 payments, Defendant Wiederhorn knew the truth behind the undisclosed illicit pay-
26 ments, including the Company’s role in the transactions. As the CEO, his scienter is
27 imputed to the Company.” (Complaint ¶73.) There are *no* allegations (let alone
28

1 particularized factual allegations) even purporting to show Kuick's scienter with
2 respect to this statement.⁷

3 If anything, the Complaint's allegations, and the allegations in the Indictment
4 and SEC Complaint upon which it relies, all but foreclose the possibility of inferring
5 that Kuick acted with scienter. The press release announcing the U.S. Attorney's
6 Indictment alleges that Wiederhorn "mispresented and concealed the true nature of
7 the payments from defendant FAT's Board, its independent auditors, its minority
8 shareholders, the [SEC], and the broader investing public." (Complaint ¶101.) The
9 Indictment and SEC Complaint both similarly allege that the Company's Board was
10 kept in the dark with respect to the Intercompany Loans, emphasizing that they were
11 *not* approved by the Board (with the exception of just \$2.05 million in approved
12 loans in 2020). (RJN Ex. B, ¶1 (alleging that Wiederhorn attempted to conceal the
13 true nature of the payments from defendant FAT's Board of Directors"); *id.* ¶¶5, 100-
14 102 (alleging that Intercompany Loans were issued to FCCG in the second through
15 fourth quarters of 2020 without the requisite Board approval); RJN Ex. C, ¶¶5, 54,
16 55, 65 (alleging that Wiederhorn "misled FAT's board of directors" and auditors).)

17 The court's analysis of the CFO's scienter in *Nathanson v. Polycom, Inc.*, 87
18 F. Supp. 3d 966 (N.D. Cal. 2015), is instructive. There, as here, the plaintiffs' allega-
19 tions of scienter against the CFOs were primarily based on: (1) certifications signed
20 by the CFOs on the company's financial statements, which added "nothing substantial
21 to the scienter calculus"; and (2) the fact that the CFOs had to sign off on all company
22 expense reports." *Id.* at 980-81.⁸ The court agreed with the CFOs that "the strongest
23

24 ⁷ Rosen, who allegedly served as the Company's Co-CEO from May 1, 2023 to the
25 present (Complaint ¶19), is not alleged to have any liability with respect to the
26 Company's alleged failure to disclose related party transactions in the 2021 Annual
27 Report or 2022 Prospectus. (*Id.* ¶¶71, 76.)

28 ⁸ "Sarbanes-Oxley certifications [by the individual defendants] are not sufficient,
29 without more, to raise a strong inference of scienter." *Glazer*, 549 F.3d at 747-48.
30 The standard language required in such certifications "add[s] nothing substantial to
31 the scienter calculus." *Zucco*, 552 F.3d at 1003-04.

1 inference is not that they were complicit in [the CEO’s] misconduct or misleading
2 shareholders, but rather that they too were duped by [the CEO].” *Id.* Similarly, here,
3 plaintiff’s recitation of *Harris*’s allegation that “there was never a business justifica-
4 tion for these loans” (Complaint ¶59), if anything, further suggests that Kuick, who
5 joined the Company *after* the Intercompany Loans were already dissolved in the
6 December 2020 Merger, did not have any knowledge of, much less involvement in,
7 the alleged scheme. Thus, based upon the allegations in the Complaint (and the
8 Indictment and SEC Complaint upon which it relies), the stronger and far more
9 plausible competing inference is that Kuick too was kept in the dark.

10 **2. No Alleged Facts Give Rise to a Strong Inference That Any
11 Defendant Knew That the Company Was a Target of U.S.
12 Attorney’s Investigation**

13 Again, the Complaint does not allege *any* facts showing when the Company
14 purportedly became a target of the U.S. Attorney’s investigation, and so plaintiff
15 cannot establish that the Company’s statement that it did not believe it was currently
16 the target of that investigation was false or misleading. Similarly, the Complaint does
17 not contain *any* facts purporting to show the point at which—if ever—any defendant
18 actually learned (or even should have learned) that the Company had become a target.
19 This is fatal to plaintiff’s ability to establish any defendant’s scienter.

20 Instead, the Complaint relies entirely on a “should have known or were reckless
21 in not knowing” theory to establish defendants’ scienter with respect to the existence
22 of government investigations. (*Id.* ¶¶75, 81, 87, 91, 94.) Specifically, plaintiff theor-
23 izes generally that “*If* the Company was indeed responding to the government’s
24 requests . . . Defendants should have known, or were reckless in not knowing, that
25 FAT Brands was a target of the investigation for its role in funneling money from
26 investors to [Wiederhorn].” (*Id.* ¶¶ 75, 81, 88, 91, 94 (emphasis added).) But the
27 Ninth Circuit is clear that “[d]eliberate recklessness is not ‘*mere* recklessness.’
28 Instead, it is ‘*an extreme* departure from the standards of ordinary care . . . which

1 presents a danger of misleading buyers or sellers that is either known to the defendant
2 of so *obvious* that the actor must have been aware of it.” *Prodanova*, 993 F.3d at 1106
3 (citation omitted) (emphasis added).

4 The Complaint does not include any allegations identifying (1) what documents
5 or materials relating to the transactions the government requested; (2) what documents
6 defendants provided in response; or (3) what those documents supposedly showed.
7 Plaintiff implicitly concedes that he does not have any such necessary facts by
8 alleging in the alternative that defendants in truth were *not* cooperating with the
9 government’s investigation. (Complaint ¶¶81, 88, 91, 94.) Without such alleged
10 facts, the Complaint raises no inference that the danger of misleading buyers or sellers
11 was so obvious that defendants *must* have been aware of it.

12 The Complaint is even more barren as to Kuick’s or Rosen’s scienter regarding
13 the Company’s alleged status as a target of government investigations. Their alleged
14 scienter is based on *the Company’s* purported “role in funneling money” to FCCG
15 and ultimately Wiederhorn. (*Id.*) The Complaint, however, contains no facts
16 showing the Company itself had any active or knowing “role in funneling money”
17 to FCCG and ultimately to Wiederhorn. Instead, the Complaint (and the Indictment
18 and SEC Complaint) emphasize that the Intercompany Loans were *not* approved by
19 the Board, that the Board was *misled* with respect to the purpose of any approved
20 loans, and thus, that FAT Brands was the direct victim of Wiederhorn’s allegedly
21 “illicit” scheme. And, critically, no allegations show that the information in the
22 requested documents or materials could have illuminated Kuick or Rosen (much less
23 did illuminate them) regarding the Company’s alleged and non-descript “role in fun-
24 neling money from investors to Defendant Wiederhorn” that purportedly occurred
25 before they joined the Company. (*Id.*; *see also id.* ¶¶18, 19.)⁹ As there are no facts
26

27 ⁹ Plaintiff’s speculation that, “[i]f Defendants Kuick and Rosen had” conducted inter-
28 views and reviewed the Company’s records, “they would have discovered the illicit
payments from FAT Brands to FCCG and Defendant Wiederhorn” (Complaint ¶88)

1 showing that Kuick or Rosen actually knew or even suspected that the Company had
2 any such role, there can be no inference that they acted with scienter. The Complaint
3 also does not allege when—if at all—during the Class Period Kuick or Rosen should
4 have known of or discovered Wiederhorn’s supposed scheme.

5 Where a complaint “does not contain additional detailed allegations about the
6 defendants’ actual exposure to information, it will usually fall short” of the PSLRA
7 standard. *South Ferry LP, No. 2 v. Killinger*, 542 F.3d 776, 784 (9th Cir. 2008). In
8 such cases the inference that defendants had knowledge of the relevant facts will not
9 be much stronger, if at all, than the inference that defendants remained unaware. *Id.*;
10 *see also ESG Capital Partners, LP v. Stratos*, 2013 WL 12131355, at *5 (C.D. Cal.
11 June 26, 2013) (conclusory allegations of knowledge are insufficient). With no alle-
12 gations regarding Kuick’s or Rosen’s actual exposure to information rendering their
13 alleged statements and omissions false or misleading, the claim fails.

14 Nor is there any allegation that either stood to benefit in any way from
15 Wiederhorn’s alleged scheme, much less from deceiving investors. The Complaint
16 does not contain *any* allegations that Kuick or Rosen personally or financially bene-
17 fited from the alleged inflation in the Company’s stock price or otherwise bought or
18 sold stock during the alleged class period. The Ninth Circuit has recognized that “a
19 lack of stock sales can detract from a scienter finding.” *Webb v. SolarCity Corp.*,
20 884 F.3d 844, 856 (9th Cir. 2018).

21 As a whole, the Complaint’s allegations do not come close to supporting a
22 *strong* (*i.e.*, cogent and compelling) inference that Kuick or Rosen knowingly or
23 recklessly intended to mislead investors by failing to disclose a scheme which they
24 may not even have known about.

25
26

27 lacks specificity and strains credulity. Based upon plaintiff’s other allegations, the
28 alleged scheme at the heart of the Complaint, the Indictment and the SEC Complaint
is that Wiederhorn’s scheme spanned over a decade, the Board was intentionally
kept in the dark and it even took the DOJ and SEC three years of investigating before
filing their Indictment and Complaint.

1 **F. The Complaint Fails to State a Controlling Person Liability Claim for**
2 **Violation of Section 20(a)**

3 Section 20(a) of the Exchange Act, 15 U.S.C. § 78t(a), creates liability for
4 “controlling persons.” 15 U.S.C. § 78t(a). “To establish a cause of action under this
5 provision, a plaintiff must first prove a primary violation of underlying federal
6 securities laws, such as Section 10(b) or Rule 10b-5, and then show that the defendant
7 exercised actual power over the primary violator.” *NVIDIA*, 768 F.3d at 1052
8 (citation omitted). As demonstrated above, plaintiff fails to state a primary violation
9 of Section 10(b) and Rule 10b-5. Accordingly, plaintiff also fails to state a secondary
10 controlling person liability claim under Section 20(a). *Nguyen v. Endologix, Inc.*, 962
11 F.3d 405, 419 (9th Cir. 2020).

12 Further, with respect to plaintiff’s claim against Kuick and Rosen, the
13 Complaint contains nothing but barebones and generic allegations of control. (Com-
14 plaint ¶ 21). These allegations are insufficient to show actual control over the Com-
15 pany. *Purple Mt. Trust v. Wells Fargo & Co.*, 432 F. Supp. 3d 1095, 1106 (N.D. Cal.
16 2020); *see also Abadilla v. Precigen, Inc.*, 2022 U.S. Dist. LEXIS 96808, at *33 (N.D.
17 Cal. May 31, 2022).

18 **V. CONCLUSION**

19 The Court should grant the motion to dismiss the Complaint.

20 Dated: June 6, 2025 SHEPPARD, MULLIN, RICHTER & HAMPTON LLP

21
22 By: _____ */s/ John P. Stigi III*
23 JOHN P. STIGI III
POLLY TOWILL
24 Attorneys for Defendants
25
26
27
28

CERTIFICATION OF WORD COUNT

2 The undersigned, counsel of record for FAT Brands, Inc., Andrew
3 Wiederhorn, Kenneth Kuick and Robert Rosen, certifies that this brief contains
4 6,960 words, which complies with the word limit of Local Rule 11-6.1.

6 | Dated: June 6, 2025 SHEPPARD, MULLIN, RICHTER & HAMPTON LLP

By: _____ */s/ John P. Stigi III*
JOHN P. STIGI III
POLLY TOWILL
Attorneys for Defendants